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Inﬂuence of Physiological Gastrointestinal Surfactant Ratio on the
Equilibrium Solubility of BCS Class II Drugs Investigated Using a Four
Component Mixture Design
Zhou Zhou, Claire Dunn, Ibrahim Khadra, Clive G. Wilson, and Gavin W. Halbert*
Strathclyde Institute of Pharmacy and Biomedical Sciences, University of Strathclyde, 161 Cathedral Street, Glasgow G4 0RE, United
Kingdom
ABSTRACT: The absorption of poorly water-soluble drugs is inﬂuenced by the luminal gastrointestinal ﬂuid content and
composition, which control solubility. Simulated intestinal ﬂuids have been introduced into dissolution testing including
endogenous amphiphiles and digested lipids at physiological levels; however, in vivo individual variation exists in the
concentrations of these components, which will alter drug absorption through an eﬀect on solubility. The use of a factorial design
of experiment and varying media by introducing diﬀerent levels of bile, lecithin, and digested lipids has been previously reported,
but here we investigate the solubility variation of poorly soluble drugs through more complex biorelevant amphiphile
interactions. A four-component mixture design was conducted to understand the solubilization capacity and interactions of bile
salt, lecithin, oleate, and monoglyceride with a constant total concentration (11.7 mM) but varying molar ratios. The equilibrium
solubility of seven low solubility acidic (zaﬁrlukast), basic (aprepitant, carvedilol), and neutral (fenoﬁbrate, felodipine,
griseofulvin, and spironolactone) drugs was investigated. Solubility results are comparable with literature values and also our own
previously published design of experiment studies. Results indicate that solubilization is not a sum accumulation of individual
amphiphile concentrations, but a drug speciﬁc eﬀect through interactions of mixed amphiphile compositions with the drug. This
is probably due to a combined interaction of drug characteristics; for example, lipophilicity, molecular shape, and ionization with
amphiphile components, which can generate speciﬁc drug−micelle aﬃnities. The proportion of each component can have a
remarkable inﬂuence on solubility with, in some cases, the highest and lowest points close to each other. A single-point solubility
measurement in a ﬁxed composition simulated media or human intestinal ﬂuid sample will therefore provide a value without
knowledge of the surrounding solubility topography meaning that variability may be overlooked. This study has demonstrated
how the amphiphile ratios inﬂuence drug solubility and highlights the importance of the envelope of physiological variation when
simulating in vivo drug behavior.
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1. INTRODUCTION
The in vivo bioavailability of orally administered drugs is
inﬂuenced by the gastrointestinal tract (GIT) through several
factors including solubility, dissolution, intestinal permeability,
and metabolism.1 For poorly soluble drugs, an important factor
is solubility, which in the gastrointestinal tract is inﬂuenced by
the variable composition of the intestinal ﬂuid2 either due to
natural biological variation3,4 or changes from a fasted to a fed
state after eating.5
1.1. Development of Simulated Intestinal Fluid. To
imitate the in vivo solubility behavior in vitro, simulated
intestinal ﬂuids representing the fasted (FaSSIF) and fed
(FeSSIF) states were developed by employing known
physiologically relevant conditions (e.g., pH) and concen-
trations of components (e.g., bile salt and lecithin).1,6 Over
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time several studies have modiﬁed the original recipes to more
closely mimic the available physiological data; for example, pH,
osmolality, surface tension, and the in vitro behavior of poorly
soluble drugs in sampled human intestinal ﬂuid. In fasted
simulated media, for example (Table 1), the biorelevant
surfactants bile salt and lecithin can aﬀect the solubility and
dissolution of poorly soluble drugs,7 and changes to the bile salt
and phospholipid concentrations were introduced. Further
studies examined the impact of pure bile salts and osmolality
adjusting agents8 along with diﬀerent concentrations of
components9 at the extremes of the known ranges. An updated
fasted recipe (FaSSIF-V2) was introduced reducing the
concentration of lecithin to 0.2 mM, which increased the bile
salt/lecithin ratio to 15:1, along with adjustment to mimic the
in vivo osmolality.10 Further data from the analysis of human
intestinal ﬂuids suggested the presence and inﬂuence of free
fatty acids and cholesterol,11,12 and a modiﬁcation to include
these (FaSSIF-V2-plus) was developed. The bile salt/lecithin
ratio can be quite variable among individuals,13 with ranges
from 2.5:1 to 15:1 in fasted and fed states, although the fed
state variation was generally smaller.4,14,15 A further updated
version of FaSSIF media has recently been proposed and
investigated (FASSIF-V3) with various prototypes of this media
being constructed with the addition or exclusion of diﬀerent
bile salts and cholesterol.16
1.2. Human Intestinal Fluid. Research into human
intestinal ﬂuid is hampered by the anatomical diﬃculty of
sampling via a nasal or oral catheter; however, concomitant
research to the development of the simulated ﬂuids has
continuously expanded and reﬁned knowledge around the
composition and properties of this complex biological material.
This has permitted an ever expanding analysis of the
physicochemical properties of the ﬂuid,3,4 providing composi-
tional data on both the fasted and fed states5,15 and samples for
solubility determinations.17 The solubility behavior of poorly
water-soluble drugs is dependent upon ﬂuid composition
especially the biorelevant surfactants such as bile salt, lecithin,
free fatty acid, and monolgyceride.18,19 Recent ultrastructural
characterization indicates that intestinal ﬂuid is composed of a
range of micellar, vesicular, colloidal, and lipid droplet systems
with the ratio of each system dependent upon the composition
and fed or fasted state.20 Human intestinal ﬂuid therefore
represents a complex multicomponent media where any one
component or combination of components has the possibility
to inﬂuence drug solubility.
1.3. Simulated Intestinal Media Solubility. The
application in vitro of ﬁxed recipe simulated intestinal media
only provides a single-point solubility measurement and cannot
represent in vivo variability of intestinal ﬂuid composition and
solubility throughout this complex space. A number of studies
have approached the impact of the variation of intestinal media
component concentrations on solubility, for example, the
solubility of danazol has been linearly related to bile salt
concentration7 in sampled human intestinal ﬂuid and solubility
of multiple poorly soluble drugs linked to a “complex interplay”
of factors.5 The solubility of poorly soluble drugs is also known
to vary between the diﬀerent simulated media recipes
sometimes by almost an order of magnitude.16,21 A statistical
exploration using a fractional factorial design of experiment
(DoE) of the solubility eﬀect of the measured human intestinal
ﬂuid ranges of various factors in fasted, and fed media22,23
indicates that a two or three log variation in solubility is
possible. The DoE studies highlighted that media pH is a major
driver for the solubility of ionizable drugs, especially acidic,
while for all drugs, buﬀer, salt, and pancreatin had no or limited
impact. For poorly soluble basic or nonionizable drugs,
biorelevant surfactants and complex drug speciﬁc interactions
between combinations of factors were important. A similar
hypothesis was presented by Clarysse and colleagues that shows
the amphiphilic contents play a major role in nonionized drugs
(danazol, nifedipine), while pH has a greater inﬂuence on the
solubility range for ionizable drugs (diazepam).5 The DoE
studies also suggested interesting drug speciﬁc solubility
variations induced by media components;22,23 however, the
experimental approach did not visualize the subtle interplay of
component concentrations and ratios on solubility.
1.4. Four Component Mixture Design. To investigate
and visualize potential interactions between the biorelevant
amphiphiles bile salt, lecithin, oleate, and monoglyceride on the
solubilization capacity of simulated intestinal ﬂuids, we have
conducted a solubility study in which the total amphiphile
concentration is maintained at a physiological concentration
equal to the fasted simulated intestinal media. This was
performed as a four-component mixture design (4MD)
equilibrium solubility study consisting of the four aforemen-
tioned amphiphiles at various molar ratios, but with a constant
Table 1. Literature Composition of Fasted Simulated Intestinal Fluid
Sunesen et al.,
20059
component/parameter
and concentration (mM)
Dressman et
al., 19981
Galia e al.,
19986
Pedersen et
al., 20007
Vertzoni et
al., 20048 low high
Jantratid et
al., 200810 V2
Psachoulias et al.,
201211 V2-plus
Fuchs et al., 201516
V3 GC/TC-Chol
sodium TC 5 3 3 2.5 6.3 3 3 1.4
sodium GC 3.7 1.4
lecithin 1.5 0.75 0.9 0.75 0.5 1.25 0.2 0.2 0.035
lysolecithin 0.315
sodium oleate 0.56 0.315
cholesterol 0.2 0.2
NaH2PO4 (K) 29 (K) 28.6 50 28.66 (K) 29 (K) 29 13.51
NaOH qs qs ∼13.8 34.8 3.19
NaCl (K) 220 (K) 103.3 150 (total
Na)
106 no salt
(KCl)
no salt
(KCl)
68.62 91.62
pancreatin 100 U/mL
tris/maleic acid 19.12
osmolality (mOsmol) 280−310 270 ± 10 270 ± 10 180 ± 10 220 ± 10
pH 6.8 6.5 6.5 6.5 6.8 6.8 6.5 6.7 ± 0.05
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total molar concentration (11.7 mM) representing the fasted
state.22 4MD has been previously applied to investigate the
phase behavior of phospholipids24 in cell membranes but have
not been applied to intestinal ﬂuid mixtures. Only Biopharma-
ceutics Classiﬁcation System (BCS) Class II drugs, which
exhibited remarkably high magnitudes of solubility in the
presence of oleate, lecithin, and bile salt, were selected from the
previous studies,22,23 with representative acid, base, and neutral
drugs (Table 2). Based on published DoE studies,22,23 the
behavior of oleate in the 4MD will depend on solution pH, and
in order to eliminate this eﬀect, the 4MD was only conducted
at pH 7 where oleate will be predominantly ionized. The buﬀer
and salt concentrations were also kept at biorelevant levels
identical to the previous DoE, which demonstrated that they do
not inﬂuence solubility. The 4MD has not previously been
applied to this problem and will provide a direct visualization of
the solubility proﬁle within the media component space
investigated.
2. MATERIALS AND METHODS
2.1. Materials. Hydrochloric acid (HCl), potassium
hydroxide (KOH), acetic acid, sodium dihydrogen orthophos-
phate (NaH2PO4), sodium chloride (NaCl), chloroform,
griseofulvin, spironolactone, and fenoﬁbrate were sourced
from Sigma-Aldrich, U.K. Aprepitant, carvedilol, felodipine,
and zaﬁrlukast were kindly provided through the OrBiTo
initiative through Dr R. Holm, Head of Preformulation,
Lundbeck, Denmark. The four amphiphiles in this particular
study will be denoted as BS, PL, OA, and MG. Sodium
taurocholate (BS) was purchased from Sigma-Aldrich; Lecithin
S PC (phosphatidylcholine from Soybean “98%”, PL) was
purchased from Lipoid, Germany; sodium oleate (OA) was
obtained from BDH Chemical Ltd. Poole England; mono-
glyceride (MG) was a gift from Croda International. All water
used was ultrapure Milli-Q water. Methanol and acetonitrile
were HPLC grade (VWR, U.K.), and ammonium acetate was
obtained from Merck, Germany.
2.2. Mixture Design and Equilibrium Solubility
Measurements. From the previous DoE, the combinations
of BS, PL, and OA are displayed in Table 3. A medium total
amphiphile concentration (11.7 mM) was chosen for the 4MD
study. 4MD contained 39 compositions in the tetrahedron
contour plot, including four compositions inside the tetrahe-
dron and 35 compositions on the four surfaces of the
tetrahedron. Each face represented a phase with the absence
of one of the four amphiphiles, and therefore, the four faces are
represented as BS/PL/OA, BS/PL/MG, BS/OA/MG, and PL/
OA/MG. Each face had 15 combinations, with ﬁve points on
the side shared by two faces (Figure 1). The concentrations
were given in mol % of the total molar concentration. The
water content was more than 99 wt % for all the compositions,
indicating this was a dilute system.
Table 2. Physicochemical Properties and Molecular Structures of Drugs Used in 4MD
aACD classic calculated values: www.acdlabs.com.
Table 3. Concentration (mM) of Three Amphiphiles Used in
the Previous DoE Based on Physiological Levels
DOE BS PL FA total concentration
1 1.5 0.2 0.5 2.2
2 1.5 1 0.5 3
3 5.9 0.2 0.5 6.6
4 5.9 1 0.5 7.4
5 1.5 0.2 10 11.7
6 1.5 1 10 12.5
7 5.9 0.2 10 16.1
8 5.9 1 10 16.9
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The 4MD was constructed using Minitab 16.0 and simplex
lattice with four component input. The lattice incorporated
four variables, and the design was augmented with axial points,
which included points in the center of the tetrahedron rather
than just the surface. The solubility data were analyzed in
Minitab 16.0 to ﬁt into quadratic and special cubic models.
Solubility data was also ﬁt into multiple ternary contour plots
with smoothing.
Phosphate buﬀer containing 68 mM NaCl and 45 mM
NaH2PO4 was prepared with deionized water and pH adjusted
to 7. Stock solutions at 11.7 mM of BS and OA were freshly
prepared from solids by dissolving in the phosphate buﬀer. The
PL stock solution was prepared by dissolving lipid in
chloroform, removing the chloroform by evaporation under
nitrogen, and dispersing the dried PL ﬁlm into phosphate
buﬀer. MG cannot dissolve in buﬀer, so the stock MG was
prepared by mixing BS (1 mM) and MG (10.7 mM) making a
total concentration of 11.7 mM, and for practical experimental
reasons, this solution was employed as 100 mol % MG. The
required 4MD media was prepared from the stock solutions
and equilibrium solubility determined in duplicate.
An excess amount of solid drug was then added to 4 mL of
each mixed lipid media in Corning 15 mL centrifuge tubes and
then placed on a rotating wheel mixer for 1 h. If required the
pH was adjusted back to 7. Tubes were then placed on the
mixer and equilibrated at 37 °C for 24 h, pH being checked
after incubation. This time frame and procedures have
previously been shown to provide equilibrium solubility.22
The saturated supernatant was separated by centrifugation at
13,000 rpm for 5 min and transferred for HPLC analysis using
an Agilent Technologies 1260 Series Liquid Chromatography
system with Clarity Chromatography software. Individual
HPLC conditions are presented in Table 4.
For the BS/PL/OA mixture design surface only, the zeta
potential of each of the mixed samples was measured by using
Malvern clear disposable zeta cell (DTS 1060C) on a Malvern
Zetasizer Nano instrument. Results indicate that drug loading
did not markedly aﬀect the measured zeta potentials of the
mixed solutions (data not shown).
3. RESULTS
3.1. Equilibrium Solubility. Figure 1b−h presents the
solubility contour plots determined by the 4MD experiment for
each drug (excluding the data points inside the tetrahedron) for
an aqueous system containing a total amphiphile concentration
at 11.7 mM. The main triangle consists of four smaller triangles
Figure 1. Solubility contour plot determined by the 4-component mixture design (4MD) experiment. The main triangle consists of four smaller
triangles representing the four surfaces of the tetrahedron when open from the top vertex, which is 100 mol % BS. The color shades attached to
individual ﬁgures represent the solubility contour concentration (mM) values for each drug, note solubility ranges vary. In panel a, 4MD
measurement points, red line indicates media containing BS/PL ratio of 4/1, representing FaSSIF, and the blue line indicates media with ratio of 15/
1, representing FaSSIF II (see Table 1). BS, bile salt; OA, sodium oleate; MG, glyceryl monooleate; PL, soya phosphatidyl choline.
Table 4. HPLC Assay Conditions15,31a
drug mobile phase column
ﬂow rate
(mL/min)
injection volume
(μL)
detection
(nm)
retention time
(min) r2
aprepitant ACN/0.05 M ammonium acetate (60:40)
pH 4.5
2 1 10 220 2.2 1.0000
carvedilol ACN/0.05 M ammonium acetate (55:45)
pH 4
2 1 10 243 2.2 0.9993
felodipine methanol/water(75:25, v/v) 2 1 20 260 5 0.9999
fenoﬁbrate ACN/water (70:30 v/v) 1 1 100 291 3 1.0000
griseofulvin ACN/water (50:50 v/v) 2 0.5 10 291 3.7 0.9970
spironolactone ACN/water (50:50 v/v) 1 1 10 238 3 1.0000
zaﬁrlukast ACN/10 mM phosphate buﬀer pH 6 50:50 1 1 10 245 2.2 0.9989
aColumn 1: Speck and Burke ODS-H optimal 150 × 30 mm id 5 μm. Column 2: Agilent Polaris 5 C18-A 150 × 4.6 MM id 5 μm. ACN, acetonitrile;
TFA, triﬂuoroacetic acid.
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representing the four faces (where each face is a ternary
contour plot with the absence of one of the four amphiphiles)
of the tetrahedron when open from the top vertex, which is 100
mol % BS. The color shades indicate solubility diﬀerences, with
black representing the highest solubility and white the lowest.
From Figure 1b−h, it is evident that each of the seven drugs has
a unique proﬁle, none have identical high solubility zones, and
that the extent and variability of solubility is diﬀerent for each
drug. The individual solubility data points on the tetrahedron’s
faces for each drug in the 4MD analysis are presented in Figure
2; the ﬁfth column displays the additional four points inside the
tetrahedron, which involve all amphiphiles. These data show
interesting diﬀerences; for example, the solubility of spirono-
lactone and griseofulvin varies in a narrow range, while others
(i.e., carvedilol) show a 250-fold variation. This demonstrates
that for each drug the four faces almost reﬂect the same range
of drug solubility, with a few exceptions that did not cover the
lower solubility points. Speciﬁcally, the BS/PL/OA combina-
tion for carvedilol did not cover solubility below 0.1 mM, while
the other three faces have. Examination of the points inside the
tetrahedron, which include all four amphiphiles, did not reveal a
greater extent of solubility variability. Additionally, it is noted
that each drug shows a diﬀerent behavior with regard to the
contribution of the four biorelevant amphiphiles, for example,
the solubility of zaﬁrlukast only increases when the proportion
of PL increases, while carvedilol solubility is sensitive to OA
concentration. In the case of fenoﬁbrate and felodipine, the four
amphiphiles in combination would provide better solubility
(Figure 1 and Table 5).
3.2. Statistical Analysis. The standardized eﬀect value for
each amphiphile can be calculated by dividing coeﬃcient with
standard error, which is similar to a p-value and thus indicates
the eﬀects in the model that are statistically signiﬁcant (Figure
3a-c). There is no p-value generated for each 100% amphiphile
(single terms), but only standardized eﬀect values to show the
magnitude. The standardized eﬀect values of each single
amphiphile are closely related with the solubility in the media
that has 100 mol % of that amphiphile, thus the higher the
value, the higher the solubility within the pure amphiphile. OA
exhibits the highest inﬂuence on solubility for six out of seven
drugs, while BS and MG have the least solubilization eﬀect on
their own. For two amphiphile interactions (Figure 3b), 17 out
of a possible 40 two combinations had a statistically signiﬁcant
positive standardized eﬀect on solubility and three had a
statistically signiﬁcant negative standardized eﬀect on solubility,
with more than half of the possible amphiphile interactions not
signiﬁcantly inﬂuencing solubility. For example, MG with OA
negatively aﬀects carvedilol solubility, MG with PL negatively
impacts zaﬁrlukast solubility and BS with OA negatively
impacts griseofulvin solubility. The three amphiphile inter-
actions (Figure 3c) are only statistically signiﬁcant in nine out
of 20 eight possible occurrences and eight of these have a
negative eﬀect on solubility with the combination of MG/BS/
PL negatively impacting four out of the seven drugs. Except for
zaﬁrlukast, OA exhibited a dominantly signiﬁcant positive eﬀect
Figure 2. Equilibrium solubility measurements of 4MD. (green) Reported solubility values for each drug in HIF, (red) reported solubility values for
each drugs in FaSSIF II media, and (black) reported solubility values for each drug in FaSSIF I media; all values are from refs 2 and 18. Equilibrium
solubility of each drug in media with the absence of one amphiphile (four surfaces of the tetrahedron, named after the amphiphile initials; for
example, BPO represents media containing BS, PL, and OA, with no addition of MG), and “mid” represents media in combination of four
amphiphiles, which are therefore inside the tetrahedron.
Table 5. Composition (Molar Ratio of Amphiphiles) of Media with the Highest and Lowest Three Solubilities of Each Drug
aprepitant griseofulvin felodipine fenoﬁbrate spironolactone zaﬁrlukast carvedilol
high
solubility
zone
75% PL, 25% OA 25% MG, 75% OA 25% MG and PL,
50% OA
12.5% BS, MG, and PL,
62.5% OA
25% MG, 75%
OA
25% MG, 75%
OA
25% PL, 75%
OA
25% MG and PL,
50% OA
12.5% BS, MG, and PL,
62.5% OA
25% BS and PL,
50% OA
75% PL, 25% OA 25% BS and OA,
50% PL
100% PL 25% BS, 75%
OA
50% MG, 50%
OA
75% PL, 25% OA 50% BS, 50% PL 12.5% BS, PL, and OA,
62.5% MG
25% BS, 75% OA 50% MG, 50%
OA
100% OA
low solubility
zone
100% PL 100% PL 100% PL 100% BS 25% BS, 75% PL 100% MG 100% MG
100% BS 100% MG 100% BS 100% MG 100% MG 25% BS, 75% OA 75% MG,
25% OA
75% BS, 25% OA 25% BS and PL, 50%
MG
100% MG 75% BS, 25% OA 75% MG, 25%
OA
25% BS and MG,
50% PL
50% MG,
50% OA
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for all drugs. Aprepitant is positively aﬀected by MG while the
other drugs, zaﬁrlukast and carvedilol are not and the PL/MG
negatively impacts zaﬁrlukast in contrast to carvedilol and
aprepitant. OA has a marked eﬀect on carvedilol, and the
presence of MG in the media reduces its solubility.
Minitab ﬁts the data generated from the design of mixtures
into quadratic and special cubic models; however, the
determinant coeﬃcient r2 (<0.8) is not signiﬁcant for any of
the drugs. This indicates that the predictors (amphiphile ratio/
concentration) in the model are not suﬃcient to explain the
solubility variation of the drugs. Drug induced drug−micelle
Figure 3. Standardized eﬀect values of (a) individual amphiphiles for each drug; (b) two-amphiphile interactions; (c) three-amphiphile interactions;
and (d) each drug. Factors/interactions are in decreasing order of magnitude. Bars over the dashed line show statistical signiﬁcance.
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interaction is also a possible factor,14 which was not included in
the model due to the limited drug property diversities. A simple
linear correlation to ﬁt the total ratio (x, expressed as mol
proportion of the total 11.7 mol) of one to two of the
amphiphiles and the drug solubility (y, mM) was attempted.
However, only the BS ratio has a negative linear relationship
with aprepitant (r2 = 0.7164) and fenoﬁbrate (r2 = 0.716). Only
two out of 28 possibilities showed linearity, which indicates the
nonlinear nature of the analysis, and these results suggest that
the systems undergo a more complicated interaction between
the amphiphiles and the drugs rather than simply a sum of
solubilization capacity of individual components.
Vertices, which represent single amphiphile dominated
media, tend to show poor solubilization capabilities (Table 5
and Figure 1). For example, the vertex representing 100 mol %
BS generally is light in color indicating lower drug solubility,
implying that a high ratio of BS alone did not show any
solubilization advantages for these drugs. Similarly, according to
Table 5, 100 mol % PL is in the low solubility zone of
fenoﬁbrate, aprepitant, and felodipine, and 100 mol % MG is in
the low solubility zone of fenoﬁbrate, zaﬁrlukast and carvedilol.
The only exception is that 100 mol % lecithin is in the high
solubility zone of zaﬁrlukast. Interestingly, apart from high
solubility zones, carvedilol and zaﬁrlukast illustrate extensive
low solubility zones (Figure 1 and Table 5) where the
amphiphile composition exhibits unfavorable solubilization.
4. DISCUSSION
4.1. Equilibrium Solubility. The equilibrium solubility
data of each drug’s 4MD correspond with literature solubility
values in fasted human or simulated intestinal ﬂuids (Figure 2)
and is comparable to the published fasted DoE.22 The results
also indicate that two (spironolactone and griseofulvin) out of
seven drugs tested have comparatively constant solubility across
the tetrahedron in agreement with their relative insensitivity to
changes in the fasted DoE media.22 For the other ﬁve drugs,
Figures 1 and 2 indicate that with the same total amphiphile
concentration the proportion of each component can have a
remarkable inﬂuence on solubility with, in some cases, the
highest and lowest solubility points close to each other (Table
5). The low solubility of carvedilol in BS rich systems also
agrees with literature reports that BS has a negative impact on
carvedilol solubility behavior.22,25 PL and MG are both poorly
dispersible in aqueous buﬀer without the other solubilization
agents such as BS,26 and Table 5 shows that generally 100 mol
% PL and 100 mol % MG media provide very poor
solubilization. However, PL exhibited excellent solubilization
for aprepitant, felodipine, and fenoﬁbrate, provided that an
appropriate ratio of BS or OA (see Table 5) was present. These
similarities to literature data indicate that the 4MD is exploring
a relevant solubility space for fasted simulated media and
exhibiting properties similar to previously published studies.
However, the current 4MD study utilized a series of media
containing the same total concentration of biorelevant
amphiphiles but encompassing changing ratios, a situation
that has not previously been systematically examined.
Several papers have reported the concentration-dependent
solubilizing capacity of diﬀerent biorelevant amphiphiles or
combinations of amphiphiles for drugs in simulated intestinal
ﬂuids. For danazol and probucol, a linear relationship between
solubility and total media concentration of BS, OA, and MG
was determined.27 Sunesen et al. reported the solubility of
danazol shows positive linearity in the presence of four
amphiphiles (BS, PL, OA, MG) irrespective of the type of
amphiphile used;14 a similar relationship was presented for
danazol, griseofulvin, fenoﬁbrate, cinnarazine,19 and estradiol.28
Other studies have examined the impact of various simulated
fasted media on solubility;13,16,29 however, these studies are not
fully comparable since there are amphiphile composition,
concentration, and ratio changes (Table 1) (FaSSIF6 vs
FaSSIF-V210 vs FASSIF-V2plus12 vs FaSSIF-V316) between
the systems. Nevertheless, in these systems, cyclosporine,16
nifedipine,16,19 dipyridamole,16,19 danazol,16,19 ketocona-
zole,16,19 celecoxib,16 felodipine16 and fenoﬁbrate16 all show
varying degrees of media-dependent solubility variation.
Indicating a similar although not directly comparable behavior
to that presented in the current study.
Studies into the structures present within intestinal media
indicate that these consist of colloidal micelles, vesicles, and
lipid droplets;20,30 however, comparable studies of micelle
structure to the current system are not available. One study on
simulated fasted ﬂuids indicates that these only consist of mixed
micelles,20 an observation that is likely to apply to the current
4MD experiment. Figures 1 and 2 along with Table 4 indicate
that the ratio of biorelevant amphiphiles can inﬂuence drug
solubility. Since the 4MD maintains a constant pH and salt
concentration, this variation has to be due to changing
interactions between the amphiphiles altering “micellar”
behavior or surface tension16 and subsequent interactions
with the drug to inﬂuence solubilization. However, the
statistical output for the 4MD was equilibrium solubility, and
micellar characteristics were not studied.
The lipophilicity of a drug can aﬀect how much it engages
with the lipid-rich micelles.27,29,31 Fagerberg et al. discovered
drug compounds with a log D(oct) greater than 3 that showed
increased solubilization in colloidal structures within fasted and
fed intestinal media.32 Therefore, it is not surprising to ﬁnd that
the solubility of spironolactone (log P = 2.7)33 and griseofulvin
(log P = 2.18)34 was not signiﬁcantly aﬀected by amphiphiles at
this concentration since both of them have a comparatively
lower log P than the other drugs tested (Table 2). However,
their low degree of interaction with BS−PL might also be
conformationally related to their relatively planar molecular
structure, or the lack of nonpolar motif may reduce the
hydrophobic interaction with micelles. Previous studies also
indicated that griseofulvin solubility was not heavily inﬂuenced
by the concentration of BS, PL, and OA.22 For the steroidal
drug spironolactone, Hammad and Muller (1998)35 reported a
similar phenomenon with three other steroidal drugs,
prednisolone, progesterone, and estradiol. Although carvedilol
has a similar log D, the speciﬁc interaction with bile salt (see
above) appears to dominate other solubility characteristics.
For the remaining drugs (aprepitant, fenoﬁbrate, felodipine,
zaﬁrlukast), solubility behavior is diﬃcult to attribute to any
speciﬁc drug property due to the low number of test drugs and
limited molecular diversity or congruity. Zaﬁrlukast has a
comparatively high log P (log P = 5.56), and on the BS/PL/OA
surface, its solubility is dominantly aﬀected by the concen-
tration of PL, which might be attributable to its planar and
rotatable structure, which could ﬁt between the hydrophobic
chains of PL. Additional components in the 4MD reveal
another high solubility zone for zaﬁrlukast with equal blend of
MG and OA, both of which have long alkyl chain tails. Warren
and colleagues showed in a simulation using molecular
dynamics that more lipophilic molecules tend to interact with
the amphiphile’s lipid alkane chain region, which again indicates
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interaction of the drug with the lipid system is highly
dependent on the polarity of both the drug and lipid
molecules.36 Nevertheless, apart from the multiple phase
forms and micelle sizes observed across diﬀerent ratios, no
standardized rules and clear correlation have been identiﬁed
between the composition of the media and diﬀerent drug
solubility.19
The results indicate that with the same total biorelevant
amphiphile concentration the proportion of each component
can have a remarkable inﬂuence on solubility indicating that not
only the amphiphile concentration but also the ratio of the
agents can inﬂuence drug solubility. Some of this behavior can
be ascribed to the drugs’ physicochemical properties (log P),
but the variation in proﬁle between the drugs indicates that the
speciﬁc molecular interaction or interactions between the drug
and the amphiphile system play an important role with high log
P compounds. A principal component analysis on solubility in
human and simulated intestinal ﬂuids29 indicated that a range
of structural molecular factors can be important. Results with a
larger range of drug properties and structures will be required
to provide a meaningful analysis.
4.2. Amphiphile Solubility Eﬀects. The 4MD statistical
analysis provides a standardized eﬀect value for the
contribution to solubility of each individual amphiphile and
combinations of amphiphiles (Figure 3a−d). For ﬁve of the
drugs (aprepitant, carvedilol, fenoﬁbrate, spironolactone, and
griseofulvin), the solubilizing eﬀect of oleic acid is dominant, a
result in agreement with the previous fasted simulated media
DoE.22 For zaﬁrlukast, PL, and for felodipine, an interaction
between BS and PL are the dominant solubilizing factors at
variance with the DoE where BS and OA, respectively, were the
most signiﬁcant, although the 4MD factors for each drug were
statistically signiﬁcant in the DoE. There is a total of 98 possible
signiﬁcant results (four for each amphiphile, six for dual
combinations, and four for three-way combinations for each of
the seven drugs), and 33 of these exhibit a positive eﬀect on
solubility (Figure 3d).
The 4MD also for each drug (with the exception of
fenoﬁbrate where no signiﬁcant negative eﬀects are present)
determines amphiphile combinations that signiﬁcantly neg-
atively impact solubility. This occurs in 11 of the possible 98
results, and interestingly, this is always a combination of two or
three amphiphiles with MG contributing to 10 results, BS and
PL, 7, and OA, 6. Due to statistical limitations of the previous
DoE, three-way interactions were not studied and MG was not
a factor; therefore, a complete comparison is not possible.
The remaining possible eﬀects (54 out of 98) do not
signiﬁcantly impact solubility, indicating that in the majority of
cases mixtures of amphiphiles do not interact. An eﬀect that
was also evident in the fasted DoE.22
These ﬁndings are very similar to those of the reported fasted
DoE indicating that the 4MD is examining a system that is
comparable to simulated media with a focus on the solubility
eﬀects due to the biorelevant amphiphiles. The y-axes in Figure
3d, which rank the individual and combination eﬀects, are
diﬀerent for each drug, again emphasizing the individuality of
each drug’s behavior in this system.
4.3. 4MD Advantages and Limitations. The diﬃculty of
ﬁtting 4MD data into linear models based on individual
amphiphile concentrations suggests a complicated interaction
among the amphiphiles, which is in agreement with DoE
studies in which the amphiphile component interactions were
signiﬁcant for basic and neutral compounds. For example,
signiﬁcant interactions of BS and OA aﬀected felodipine,
griseofulvin, fenoﬁbrate, zaﬁrlukast, aprepitant, and carvedilol,
while interactions with PL aﬀected fewer drugs, which might be
due to the narrow range of PL concentration utilized (0.2−1
mM).22 However, the roles and interactions of PL became
more evident in 4MD, as the range was expanded (0−11.7
mM). The dashed line in Figure 1 indicates a possible space by
providing BS/PL in a 4:1 and 15:1 ratio, with multiple levels of
either MG or OA, which best resembles the possible scenarios
in FaSSIF media.6,10 This clearly covers a set of limited
solubility variations that could happen in the intestine, and
although some of the combination ratios in the 4MD are not
physiologically relevant in the fasted state, they provide a larger
range and indicate potential risks of solubility sensitivity issues.
Although combinations of amphiphiles exhibit better
solubilization, our study incorporated four diﬀerent amphi-
philes, and the highest solubility was shown to vary from drug
to drug. BS and OA are two ionizable amphiphiles, the
carboxylate group of OA has a pKa of about 5; however, pKa
could increase considerably to above 7 in PL vesicles or other
mixed aggregates.37,38 Temperature and ionic strength can also
aﬀect the apparent pKa. These ionization changes may aﬀect
solubilization capacities of the amphiphiles and the charge
interaction with ionizable drugs. Carvedilol (pKa = 7.8, log P =
3.91)39,40 is a moderately hydrophobic and ionic compound,
which is protonated at pH 7. Our data shows solubilization is
aided by a more negatively charged system with higher OA
(75%−100% OA). The solubility distribution within the BS/
PL/OA surface of carvedilol resembles the zeta potential
contour plot (Figure 4), which implies that electrostatic
attraction becomes a predominant factor for carvedilol−micelle
interaction.
One advantage of the 4MD versus the DoE is that the levels
of amphiphiles in the previous DoE were selected based on the
physiological level, which can over emphasize one amphiphile
relative to another if the selected concentration range is
intrinsically much higher (OA, BS much higher than PL, MG).
However, in the 4MD, all four components are positioned in an
Figure 4. Zeta potential (mV) distribution in BS/PL/OA mixture (0%
MG), based on 15 diﬀerent compositions. Each point is an average
number from two measurements (processed in OriginPro 9.0.0 SR1).
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equal molar range. This approach gives more insight into the
existence of complex phase boundaries, which change
dynamically as the ﬂuids are altered down their journey from
duodenum to colon. Some of the ranges used in this approach
may exceed the physiological level in the fasted state. However,
only one total concentration was investigated in this study,
which did not reach the fed state level where even more diverse
drug behavior is to be expected. For example, griseofulvin
absorption from GIT has been shown to increase with the
administration of a high fat meal.41 This was not shown in our
study, which might be due to the limited range of this 4MD
envelope.
5. CONCLUSIONS
The current 4MD study design generates an increase in
information over the previous literature and focuses on the
inﬂuence of biorelevant amphiphiles on the equilibrium
solubility of BCS II drugs. Drugs from previous DOE
studies22,23 with a statistically signiﬁcant standardized eﬀect
value indicating biorelevant amphiphiles increase solubility
were selected, and the results provide comparable solubility
data to literature results with both human and simulated
intestinal ﬂuids. This approach generates information that
diﬀers from previous studies, where drug solubility has a linear
relationship with the total concentration of amphiphiles
regardless of the type of amphiphiles used.9,27,28
Two out of seven drugs (griseofulvin, spironolactone) in this
study with log P values less than 3 show marginal solubility
inﬂuence induced by changing the amphiphile ratios, which
adds additional information that the concentration and also the
ratio of surfactants would not aﬀect their solubility signiﬁcantly.
For the other ﬁve drugs (felodipine, fenoﬁbrate, zaﬁrlukast,
carvedilol, and aprepitant) with log P values greater than 3, the
results imply that the media solubilization capacities are not a
simple sum of the eﬀects of the four biorelevant amphiphiles
with drug lipophilicity and that more complicated interactions
and drug speciﬁc eﬀects are important. It also suggests some
insights into the drug−micelle interactions, and some of the
eﬀects observed are in good agreement with reported
studies,14,35,42 indicating that drug solubility is related to
lipophilicity with other factors, for example, molecular shape
and charge contributing. However, the unique behavior of each
drug in this study and the limited number tested does not
permit detailed conclusions to be drawn.
This result indicates that not only the amphiphile
concentration but also the ratio of the agents can inﬂuence
drug solubility and that the resulting solubility topography is
drug dependent. Therefore, a single-point solubility measure-
ment in a ﬁxed composition media will provide a value that
might be situated in a valley, plateau, slope, or peak. In
simulated media systems or in human intestinal ﬂuid samples
with a constant ratio of components, without knowledge of the
surrounding solubility topography, some variability may be
overlooked. Reproducible solubility determinations might
indicate a consistent solubility throughout the entire space
(griseofulvin, spironolactone) or a measurement on a plateau
(aprepitant), while variability may relate to measurement on a
slope. Therefore, targeting simulated media analysis to a
physiological related and compacted ratio range of bile,
phospholipids, and digested lipids while covering the
concentration of fasted and fed states would provide
information on the variation and sensitivity of drug solubility
to speciﬁc combinations of biorelevant components.
There may be opportunities to incorporate the solubility
information from the 4MD into PBPK models, which would be
useful for predicting the individual variability or disease-related
changes in the gastrointestinal ﬂuids that can aﬀect drug
bioavailability. Future studies could employ a higher concen-
tration of mixed amphiphiles that would be generated in the fed
state and pH could be altered, which is likely to provide even
more complicated systems through ionization changes to the
drug,5 the amphiphiles,37,38 and the interactions between drugs
and amphiphiles.22,23 Further studies with a larger samples of
drugs with varying molecular properties (not simply log P) or a
homologous series will be required in order to dissect the
relationship of drug properties to amphiphile-speciﬁc solubili-
zation.
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